SUMMARY / RELATED TOPICS

Rollo Duke of Normandy

Rollo Duke of Normandy known as The Bloody Brother, is a play written in collaboration by John Fletcher, Philip Massinger, Ben Jonson and George Chapman. The title character is the historical Viking duke of Rollo. Scholars have disputed everything about the play. In addition to the four writers cited above, the names of Nathan Field and Robert Daborne have been connected with the play by individual scholars. Rollo, Duke of Normandy, is locked in a struggle for power with his brother Otto. Urged on by the sycophantic LaTorch, Rollo murders Otto. After he commits a number of other bloodthirsty deeds, Rollo is lured into a private meeting with the beautiful Edith, daughter of one of his victims, who plots to murder him; as Edith hesitates, captain of the guard and brother of another of Rollo's victims, breaks in and murders Rollo. Hamond is himself killed in the process. Aubrey, Rollo's cousin, succeeds to the dukedom. Details of the play's earliest productions are not preserved in the historical record.

The play was seen at the Globe Theatre on 13 May 1633, was acted at Hampton Court Palace on 24 January 1637. It was entered into the Stationers' Register on 4 October 1639 by the booksellers John Crook and Richard Sergier, as the work of "J. B." It was first published in 1639, in a quarto printed by R. Bishop for John Crook and Thomas Allot, under the title The Bloody Brother; the title page of this quarto attributes the play to "B. J. F." A second quarto appeared in 1640 under the title The Tragoedy of Rollo Duke of Normandy, published at Oxford by stationer Leonard Lichfield, "Printer to the University." Q2 assigns the play to Fletcher, asserts that it was acted by the King's Men. Q2 appears to derive from a theatre prompt-book, while Q1 shows less sign of direct contact with the stage and is a more "literary" text; the play was included in the second Beaumont and Fletcher folio of 1679. Though the theatres were closed from 1642 to 1660, surreptitious performances occurred sporadically through the era.

1647 was a year of relative official lenience, when the actors were active. On 5 February 1648, King's Men players were arrested in the midst of a clandestine performance of Rollo at the Cockpit Theatre. Joseph Taylor was acting Rollo; the actors were arrested, imprisoned in Hatton House for a time. Scholars have been divided about the nature of the play's authorship; some have regarded it as a play, written by Jonson and Chapman and revised by Fletcher and Massinger. In his sweeping study of authorship problems in the Fletcher canon, Cyrus Hoy provided this breakdown among the shares of the four dramatists — Massinger — Act I.

Oxycodone/aspirin

Oxycodone/aspirin is a combination drug marketed by Endo Pharmaceuticals. It is a tablet containing a mixture of 4.8355 mg of oxycodone HCl. The safety of the combination during pregnancy has not been established, although aspirin is contraindicated during pregnancy, the drug has been placed in pregnancy category D. Inactive ingredients include D&C Yellow 10, FD&C Yellow 6, microcrystalline cellulose, corn starch. Percodan was first marketed by DuPont Pharmaceuticals and prescribed in the United States in 1950. Once a prescribed painkiller, it has been replaced by alternative oxycodone compounds containing paracetamol instead of aspirin, such as Percocet; the oxycodone component in the combination is technically 14-hydroxy-7,8-dihydrocodein-6-one, a white odorless, crystalline powder, synthesized from the opium alkaloid thebaine. Thebaine by itself has no therapeutic value. Oxycodone is metabolized into oxymorphone. Unlike morphine and like codeine, oxycodone has a good oral potency. Prior to the introduction of paracetamol, Percodan was the mainstay in post-operative oral pain treatment due to the potency and long half-life of oxycodone.

It contained a small amount of caffeine. The usual dose is one tablet every six hours as needed for pain; the maximum daily dose should not exceed 12 tablets. Percodan was reformulated in 2005. Since the latter salt is unusual in the pharmacopeia, the manufacturer increased the amount of oxycodone hydrochloride to 4.8355 mg and discontinued the oxycodone terephthalate. Percodan has been replaced by Percocet and other oxycodone-containing compounds for post-operative pain. Aspirin increases prothrombin time and can result in post-operative complications, such as excessive bleeding. Hydrocodone with paracetamol has gained favor. Hydrocodone as potent as oxycodone, in combined form allowed refills. In the United States, Percodan is regulated as a Schedule II controlled substance under the Uniform Controlled Substances Act of 1970; as of October 6, 2014, Percodan is becoming something of a relic in the United States, at least, as the number of prescriptions has fallen precipitously since the 1960s in light of the alternate drugs available containing oxycodone.

The combination oxycodone/aspirin is sold under the brand name Endodan. All products containing oxycodone have the potential to be habit-forming. Oxycodone can produce drug dependence of the morphine type and, has the potential for being addictive. Embeda Hypnorm Percocet Targin Vicodin Vicoprofen Percodan Prescribing Information from Endo Pharmaceuticals. Search "Percodan" in FDA Archives.